Oncology-focused CRO and research network announces its Oncology Data Warehouse includes information from over 110,000 oncology patients.
ACORN Continues Success in Oncology Data Warehousing With Accumulation of Nearly 50 Million Data Observations
MEMPHIS, Tenn., June 16 /PRNewswire/ -- Accelerated Community Oncology Research Network(TM), an oncology-focused CRO and research network, announced today that its Oncology Data Warehouse has accumulated nearly 50 million data observations from over 110,000 oncology patients contained in its data warehouse. Integrating patient-reported outcomes (PROs), electronic medical records (EMR), claims data, and laboratory information systems, garnered from community oncology practices nationwide where 85% of cancer care is provided, the warehouse contains demographically diverse data, offering reliable information on treatments and outcomes to payers, financial institutions, pharmaceutical / biotech companies, and community oncology practices.
"Our data warehouse is now mature enough to support longitudinal or cross-sectional analyses comparing practice patterns, toxicity, and outcomes in large groups of patients undergoing treatment for a broad range of tumor types," according to Ed Stepanski, Ph.D., Chief Operating Officer. "Additionally, several years of archived PACE System PROs provide a critical component to our Oncology Data Warehouse, allowing us to systematically analyze patients' symptom burden and quality of life, making our warehouse unique among all oncology data repositories."
Analytic data from this large-scale oncology data repository has been presented at many major oncology-related conferences and published in peer-
reviewed medical journals worldwide. Furthering the field of oncology health informatics, ACORN's data warehouse has been used in numerous projects that address quality of care, patients' quality of life, overall health outcomes and the cost of care.
"Determining the most effective and least toxic treatment regimens in actual clinical practice, as opposed to a clinical trial, is a valuable end result from the data warehouse," observes Steve Coplon, CEO. "ACORN will soon double the number of unique patients in the warehouse. The warehouse runs as close to real time as is needed for projects we conduct."
ACORN will exhibit at the annual Drug Information Association meeting in Boston, June 22-25, 2008. Senior level ACORN executives will be present to discuss ACORN's Oncology Data Warehouse as well as its CRO services, Guardian EDC, and network of community oncology practices. For additional information visit www.ACORNresearch.net or contact Liz Conway, Director of Marketing and Corporate Services, 901-259-0878.
Accelerated Community Oncology Research Network, Inc. (ACORN)
ACORN focuses on oncology exclusively. ACORN offers centralized clinical trial services, scientific analysis, and is a full-service Clinical Research Organization (CRO), providing contract and budgeting services; fostering accrual of subjects at the site level; collecting data and monitoring its accuracy; and working seamlessly with both trial sponsors and participating practices.
Contact Information:
Liz Conway
(901) 435-5570
lconway@sosacorn.com
www.ACORNresearch.net
Deborah D. Coble
901-683-0055x1312
dcoble@sosacorn.com
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.